Physician profile
Michael Marsh
NPI 1689961591
$8,568.13
in general payments reported to CMS, 2019-2025
10 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.85 · 2022: $4,261 · 2023: $3,238 · 2024: $435 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,143 · Gift: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,142.55 |
| Gift | $151.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,659.77 | 2022-2025 | Da Vinci Surgical System |
| Olympus America INC. | $233.75 | 2024-2025 | Spiration Valve System |
| Astrazeneca Pharmaceuticals LP | $214.33 | 2024 | Fasenra |
| Caris Mpi, INC. | $162.35 | 2025 | Mi Cancer Seek |
| Galvanize Therapeutics, INC | $89.62 | 2024-2025 | Aliya System |
| Novo Nordisk INC | $69.51 | 2025 | Rybelsus, Ozempic |
| Erbe USA INC | $65.00 | 2025 | Erbe Cryo2 |
| Glaxosmithkline, LLC. | $36.17 | 2019-2023 | Trelegy Ellipta |
| Inogen, INC. | $19.20 | 2024 | |
| Abbvie INC. | $18.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.